Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Award
Common Stock
2024-01-31+149,300→ 726,337 total - Award
Stock Option (Right to buy)
2024-01-31+224,000→ 224,000 totalExercise: $1.68Exp: 2034-01-31→ Common Stock (224,000 underlying)
Footnotes (3)
- [F1]The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
- [F2]Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
- [F3]The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.